HIV Infections
Conditions
Keywords
HIV, PEP, Doravirine, HIV exposure, HIV prevention
Brief summary
The main objective of this observational study is to assess the adherence of post exposure prophylaxis treatment with doravirine (using Delstrigo® or Pifeltro®), prescribed to subjects exposed to HIV according to French national recommendations. This study will evaluate: * the percentage of subjects who followed their treatment within the prescribed 28 days, * the prevalence and type of side effects in subjects on this treatment, * the occurrence of HIV seroconversion associated with this combination.
Detailed description
The study visits are those routinely performed in the standard care of the subjects using PEP and are the following: Visit 1 (between day 1 to day 8 after PEP treatment initiation): * Subject information and inclusion in the study, * Pregnancy test (urine or serum) for women of childbearing potential (WOCBP) * Delivery of a follow-up subject diary (daily information about PEP treatment intake, concomitant treatments and potential side effects/adverse events) Visit 2 (From 42 days to 90 days after PEP treatment initiation) * Treatment observance (PEP), * Return of the follow-up subject diary, * Check of the follow-up subject diary completion, * Keep a copy of the HIV serology and/or viral load results in the medical file.
Interventions
DRUGDoravirine
The study treatments will used during 28 days according to the routine care of each investigator center.
Sponsors
Merck Sharp & Dohme LLC
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age more than 18 years old 2. Exposure to HIV, leading to the prescription of 28-day post exposure prophylaxis (PEP) 3. PEP with doravirine: 1. Delstrigo® (tenofovir disoproxil, doravirine, lamivudine), 2. Or Pifeltro® (doravirine) in association with tenofovir disoproxil/emtricitabine. 4. Participant who can understand, read and speak French. 5. With or without health insurance. 6. Cisgender female and Female to Male transgender participants are eligible to participate if they are not pregnant or breastfeeding, and at least one of the following conditions applies: • 1. Is not a WOCBP (Women Of Childbearing Potential) OR 2. Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), or be abstinent as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the treatment period and for at least 8 weeks after the last dose. The investigator should evaluate the potential for contraceptive method failure (i.e., non compliance, recently initiated) in relationship to the first dose of PEP treatment. A WOCBP must have a negative pregnancy test (urine or serum) before inclusion in the study. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant should not be included in the study if the serum pregnancy result is positive.
Exclusion criteria
1. Contraindication to Delstrigo® or Pifeltro® or tenofovir disoproxil/emtricitabine: hypersensitivity to active substances or excipients. 2. Contra-indicated treatment likely to interfere with the study drugs as listed in the summary of the product characteristics. 3. Viral resistance of the source subject known and unsuitable for the prescription of doravirine 4. Simultaneous participation in another clinical trial with an experimental treatment or any intervention, which may have impact/change onto the PEP treatments or within an exclusion period of a previous clinical trial at screening. 5. Subjects under legal guardianship or unable to express their consent. 6. Subject privated of liberty by judicial or administrative decision or subject under psychiatric care or admitted to a health or social establishment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess the adherence of post exposure prophylaxis treatment with doravirine (using Delstrigo® or Pifeltro®), prescribed to subjects exposed to HIV according to French national recommendations. | 3 months | Proportion of subjects who complete the total period of treatment (intake during 28 days). The treatment completeness will be defined as follows: * no missing treatment intake from D1 to D14, * and no more than 2 missing treatment intakes from D15 to D28. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the tolerability of PEP with doravirine. | 28 days | Number and type of side effects. |
| To evaluate the prevalence of HIV seroconversion associated with this combination. | 3 months | Number of subjects with seroconversion. |
| To compare the adherence of post exposure prophylaxis treatment between Delstrigo® or Pifeltro® | 28 days | Proportion of subjects who complete the total period of each treatment (intake during 28 days). |
Countries
France
Outcome results
None listed